BR112015028581A2 - composição farmacêutica de dosagem baixa, utilização do ácido, método para o tratamento da doença inflamatória e composição farmacêutica - Google Patents

composição farmacêutica de dosagem baixa, utilização do ácido, método para o tratamento da doença inflamatória e composição farmacêutica

Info

Publication number
BR112015028581A2
BR112015028581A2 BR112015028581A BR112015028581A BR112015028581A2 BR 112015028581 A2 BR112015028581 A2 BR 112015028581A2 BR 112015028581 A BR112015028581 A BR 112015028581A BR 112015028581 A BR112015028581 A BR 112015028581A BR 112015028581 A2 BR112015028581 A2 BR 112015028581A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
inflammatory disease
low dosage
treatment
acid utilization
Prior art date
Application number
BR112015028581A
Other languages
English (en)
Other versions
BR112015028581B1 (pt
Inventor
Dutt Chaitanya
Abraham Jaya
Kotecha Jignesh
Chhipa Laxmikant
Gupta Ram
Gupta Ramesh
Srivastava Sanjay
Deshpande Shailesh
Zambad Shitalkumar
Chauthaiwale Vijay
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of BR112015028581A2 publication Critical patent/BR112015028581A2/pt
Publication of BR112015028581B1 publication Critical patent/BR112015028581B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

resumo “composição farmacêutica de dosagem baixa, utilização do ácido, método para o tratamento da doença inflamatória e composição farmacêutica” a presente invenção se refere a uma composição farmacêutica de dosagem baixa, de preferência, a composição oral compreende uma quantidade terapeuticamente eficaz do ácido [(2-hidroxi-4-oxo-6,7,8,9-tetraidro-4h,5h-10-tia-1,4a-diaza-benzo[a]azuleno-3-carbonil)-amino]-acético (composto a) no intervalo de 2,5 mg a 60 mg. a presente invenção também se refere a um método para o tratamento da doença inflamatória do intestino grosso em um mamífero através da administração de dita composição farmacêutica de dosagem baixa. além disso, a presente invenção se refere a uma utilização do composto a para a preparação de uma composição farmacêutica de dosagem baixa para o tratamento da doença inflamatória do intestino grosso em um mamífero.
BR112015028581-3A 2013-05-14 2014-05-12 Usos do ácido [(2-hidroxi-4-oxo-6,7,8,9-tetrahidro-4h,5h-10-tia1,4a-diaza-benzo[a]azuleno-3- carbonil)-amino]-acético BR112015028581B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN1718MU2013 2013-05-14
IN1718/MUM/2013 2013-05-14
IN2309/MUM/2013 2013-07-09
IN2309MU2013 2013-07-09
PCT/IB2014/000707 WO2014184631A1 (en) 2013-05-14 2014-05-12 Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease

Publications (2)

Publication Number Publication Date
BR112015028581A2 true BR112015028581A2 (pt) 2017-07-25
BR112015028581B1 BR112015028581B1 (pt) 2022-05-03

Family

ID=50896342

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015028581-3A BR112015028581B1 (pt) 2013-05-14 2014-05-12 Usos do ácido [(2-hidroxi-4-oxo-6,7,8,9-tetrahidro-4h,5h-10-tia1,4a-diaza-benzo[a]azuleno-3- carbonil)-amino]-acético

Country Status (27)

Country Link
US (2) US9610247B2 (pt)
EP (1) EP2996693B1 (pt)
JP (1) JP6407974B2 (pt)
KR (1) KR102239649B1 (pt)
CN (1) CN105209043B (pt)
AU (1) AU2014266968B2 (pt)
BR (1) BR112015028581B1 (pt)
CA (1) CA2912011C (pt)
CY (1) CY1121280T1 (pt)
DK (1) DK2996693T3 (pt)
EA (1) EA030590B1 (pt)
ES (1) ES2712705T3 (pt)
HR (1) HRP20190315T1 (pt)
HU (1) HUE042691T2 (pt)
IL (1) IL242490B (pt)
LT (1) LT2996693T (pt)
MX (1) MX358198B (pt)
MY (1) MY179215A (pt)
PH (1) PH12015502560B1 (pt)
PL (1) PL2996693T3 (pt)
PT (1) PT2996693T (pt)
RS (1) RS58423B1 (pt)
SG (1) SG11201509275PA (pt)
SI (1) SI2996693T1 (pt)
TW (1) TWI661828B (pt)
UA (1) UA117244C2 (pt)
WO (1) WO2014184631A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017159585A1 (ja) * 2016-03-14 2017-09-21 参天製薬株式会社 メグルミン又はその塩からなる防腐剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009002533A1 (en) 2007-06-27 2008-12-31 The Brigham And Women's Hospital, Inc. Inflammatory bowel disease therapies
TWI500623B (zh) * 2009-10-13 2015-09-21 Torrent Pharmaceuticals Ltd 新穎稠合噻唑及噁唑嘧啶酮
US8541430B2 (en) * 2009-11-27 2013-09-24 Torrent Pharmaceuticals Limited Fused thiazolo and oxazolo pyrimidinones

Also Published As

Publication number Publication date
PT2996693T (pt) 2019-02-27
CY1121280T1 (el) 2020-05-29
PH12015502560A1 (en) 2016-02-22
EA201592159A1 (ru) 2016-04-29
LT2996693T (lt) 2019-03-12
SI2996693T1 (sl) 2019-04-30
US10471005B2 (en) 2019-11-12
BR112015028581B1 (pt) 2022-05-03
RS58423B1 (sr) 2019-04-30
DK2996693T3 (en) 2019-03-18
CN105209043A (zh) 2015-12-30
AU2014266968A1 (en) 2015-12-03
TWI661828B (zh) 2019-06-11
KR20160008571A (ko) 2016-01-22
MX2015015682A (es) 2016-07-20
EP2996693B1 (en) 2018-12-12
US9610247B2 (en) 2017-04-04
HRP20190315T1 (hr) 2019-04-05
NZ714098A (en) 2020-12-18
PH12015502560B1 (en) 2016-02-22
US20170157129A1 (en) 2017-06-08
AU2014266968B2 (en) 2019-09-19
EP2996693A1 (en) 2016-03-23
US20160120801A1 (en) 2016-05-05
WO2014184631A1 (en) 2014-11-20
MY179215A (en) 2020-11-02
EA030590B1 (ru) 2018-08-31
CN105209043B (zh) 2019-07-02
UA117244C2 (uk) 2018-07-10
MX358198B (es) 2018-08-08
IL242490B (en) 2018-11-29
SG11201509275PA (en) 2015-12-30
HUE042691T2 (hu) 2019-07-29
CA2912011A1 (en) 2014-11-20
ES2712705T3 (es) 2019-05-14
JP2016518440A (ja) 2016-06-23
CA2912011C (en) 2021-10-26
PL2996693T3 (pl) 2019-05-31
TW201513866A (zh) 2015-04-16
KR102239649B1 (ko) 2021-04-12
JP6407974B2 (ja) 2018-10-17

Similar Documents

Publication Publication Date Title
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
BR112014031394A2 (pt) composições e métodos para absorção transmucosa
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
EA031157B9 (ru) Вводимая перорально кортикостероидная композиция
JP2015038135A5 (pt)
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
BR112014004435A2 (pt) inibidores de quinase rock
BR112014004732A2 (pt) composto benzotiazolona
EA201270747A1 (ru) Композиции и способы для профилактики и лечения ран
BR112014030288A8 (pt) composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila
GR1008228B (el) Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου
BR112014011336A2 (pt) composições farmacêuticas que compreendem 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetra-hidro-quinolina para tratamento de doenças e condições de pele
BR112015028581A2 (pt) composição farmacêutica de dosagem baixa, utilização do ácido, método para o tratamento da doença inflamatória e composição farmacêutica
BR112014001503A2 (pt) composições farmacêuticas compreendendo 4-bromo-n-(imidazolidin-2-ilideno)-1h-benzimidazol-5-amina para o tratamento de doenças de pele

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/05/2014, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 10A ANUIDADE.